📇 Rhumatologue · VALENCIENNES CEDEX · (59) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Praticien-chercheur
11 articles scientifiques publiés — formation continue solide
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
126.7 rhumatos / 100 000 hab. — département bien doté
11 publications sur 5 ans
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
8
8 articles ont été cités au moins 8fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
212
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
49
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
6
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre Hospitalier Universitaire de Lille · Lille’s Cardiology Hospital · Centre Hospitalier de Valenciennes
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Preserving bone in cancers of the elderly: A necessity
2023ArticleJoint Bone Spine
The role of senescence in the development of non-melanoma skin cancer in kidney transplant recipients: the impact of immunosuppressive drugs in vitro
2023Congrès2nd ONCOLIlle PhD student’s Days
Pyoderma gangrenosum developing in a patient treated with dupilumab
2021ArticleJAAD Case reports
Real-life evaluation of the treatment of actinic keratoses by textile photodynamic therapy (FLUXMEDICARE® device).
2021ArticlePhotodiagnosis and Photodynamic Therapy
Outcome of early stage Merkel carcinoma treated by exclusive radiation: a study of 53 patients
2021ArticleRADIATION ONCOLOGY
Association of transcription factor 7-like 2 gene (TCF7L2) polymorphisms with stress-related hyperglycaemia (SRH) in intensive care and resulting outcomes: The READIAB study
2020ArticleDiabetes & Metabolism
Safety and efficacy of thermal ablation (radiofrequency and laser): should we treat all types of thyroid nodules?
2019ArticleInternational Journal of Hyperthermia
Light emitting fabrics for PDT: technology and results of clinical studies
2019Congrès17th International Photodynamic Association World Congress
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CH VALENCIENNES
114 AV DESANDROUINS BP 479, 59322 VALENCIENNES CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2019
Melanoma research · 2017
BRAF inhibitors (BRAFi), a targeted therapy, are used to treat metastatic late-stage melanomas harbouring the BRAF-V600 mutation (found in about 50% of melanomas). The targeted therapy is generally maintained until tumour progression or major toxicity occurs, although responses are often limited in time. It is unknown whether melanoma patients achieving a complete response with targeted therapy can safely discontinue treatment. We retrospectively observed the clinical course of patients with metastatic melanoma who discontinued BRAFi therapy after achieving a complete response and those with an incomplete response combined with surgical removal of the remaining tumours. We also evaluated the effectiveness of BRAFi in these patients after recurrence. In 11 patients, the best response was diagnosed after a median BRAFi treatment duration of 105 (29–341) days. The median follow-up after BRAFi initiation was 769 (435–1765) days. Recurrence was observed in all 11 patients (100%), median: 82 (27–322) days. Five patients achieved a complete response, with a median progression-free survival after cessation of 136.5 (34–322) days versus 82 (27–144) days for six patients with an incomplete response combined with surgical removal of remaining tumours. Baseline characteristics and time to best response and to discontinuation did not influence the rate of relapse. Subsequently, eight patients were rechallenged with a BRAFi. The median progression-free survival time after BRAFi rechallenge was 222.5 (15–425) days. The three remaining patients received treatments other than BRAFi. Our findings may be valuable with respect to ongoing clinical trials of combinations of targeted therapies and immunomodulatory antibodies.
Lasers in surgery and medicine · 2018
BackgroundTopical photodynamic therapy is an established treatment modality for various dermatological conditions, including actinic keratosis. In Europe, the approved protocols for photodynamic therapy of actinic keratosis involve irradiation with either an Aktilite CL 128 lamp or daylight, whereas irradiation with the Blu‐U illuminator is approved in the United States. Many other protocols using irradiation by a variety of light sources are also clinically efficient.ObjectivesThis paper aims to compare 10 different protocols with clinically proven efficacy for photodynamic therapy of actinic keratosis and the available spectral irradiance of the light source. Effective irradiance, effective light dose, and local damage are compared. We also investigate whether there is an association between the complete response rate at 3 months and the effective light dose or local damage.MethodsThe effective irradiance, also referred to as protoporphyrin IX‐weighted irradiance, is obtained by integrating the spectral irradiance weighted by the normalized absorption spectrum of protoporphyrin IX over the wavelength. Integrating the effective irradiance over the irradiation time yields the effective light dose, which is also known as the protoporphyrin IX‐weighted light dose. Local damage, defined as the total cumulative singlet oxygen molecules produced during treatment, is estimated using mathematical modeling of the photodynamic therapy process. This modeling is based on an iterative procedure taking into account the spatial and temporal variations in the protoporphyrin IX absorption spectrum during treatment.ResultsThe protocol for daylight photodynamic therapy on a clear sunny day, the protocol for daylight photodynamic therapy on an overcast day, the photodynamic therapy protocol for a white LED lamp for operating rooms and the photodynamic therapy protocol for the Blu‐U illuminator perform better than the six other protocols—all involving red light illumination—in terms of both effective light dose and local damage. However, no association between the complete response rate at 3 months and the effective light dose or local damage was found.ConclusionsProtocols that achieve high complete response rates at 3 months and low pain scores should be preferred regardless of the effective light dose and local damage. Lasers Surg. Med. 50:576–589, 2018. © 2018 Wiley Periodicals, Inc.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Current oncology (Toronto, Ont.) · 2023 · Journal Article
Boileau M, Dubois M, Abi Rached H, Escande A, et al.
JAAD case reports · 2023 · Case Reports
Toulemonde E, Faiz S, Dubois R, Verhasselt-Crinquette M, et al.
JAAD case reports · 2022 · Case Reports
Nasseh J, Abi Rached H, Dumitru I, Staumont-Sallé D, et al.
Lasers in surgery and medicine · 2018 · Comparative Study
Vignion-Dewalle AS, Baert G, Thecua E, Lecomte F, et al.
Journal of the American Academy of Dermatology · 2018 · Letter
Girard E, Lacour A, Abi Rached H, Ramdane N, et al.
Melanoma research · 2017 · Journal Article
Desvignes C, Abi Rached H, Templier C, Drumez E, et al.
JAAD case reports · 2021 · Case Reports
Le Calvé C, Abi-Rached H, Vicentini C, Maire C, et al.
JMIR research protocols · 2019 · Journal Article
Vignion-Dewalle AS, Abi Rached H, Thecua E, Lecomte F, et al.
Joint bone spine · 2023 · Journal Article
Bertrand N, Bridoux M, Gaxatte C, Abi Rached H, et al.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2019 · Journal Article
Ben Hamou A, Ghanassia E, Espiard S, Abi Rached H, et al.
Photodermatology, photoimmunology & photomedicine · 2019 · Clinical Trial
Vicentini C, Vignion-Dewalle AS, Thecua E, Lecomte F, et al.